# Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

> **NCT01397968** · PHASE2 · COMPLETED · sponsor: **SK Life Science, Inc.** · enrollment: 222 (actual)

## Conditions studied

- Partial Epilepsy

## Interventions

- **DRUG:** YKP3089
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01397968
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-06
- **Primary completion:** 2013-06
- **Final completion:** 2021-01-28
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2022-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01397968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01397968, "Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01397968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*